OOIR: Observatory of International Research

Papers

(The TQCC of Alzheimers & Dementia is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
High‐fat diet reduced dendritic spine density, but it did not affect cognitive function in spontaneous diabetic torii rats	2380
RBFOX1 is regulated by the adenosine 2a receptor and is ubiquitinated in tau tangles in Alzheimer’s disease	1771
Prediction of amyloid‐beta accumulating normal cognitive elderly	1232
Lean mass, grip strength, and hospital‐associated disability among older adults in Health ABC	1156
Locus coeruleus hyperactivity in middle age may be associated with better cognitive performance	599
MRI‐guided Clustering of Alzheimer’s Disease patients: A post‐hoc analysis of Phase 3 Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease	417
Tracing synaptic loss in Alzheimer's brain with SV2A PET‐tracer UCB‐J	333
Estimated pulse wave velocity associated with cognitive phenotypes in a rural older population in China: A cohort study	326
Trajectories of Neurological Recovery 12 Months after Hospitalization for COVID‐19: A Prospective Longitudinal Study	275
HbA_1c variability associated with dementia risk in people with type 2 diabetes	201
Does Alzheimer's disease with mesial temporal lobe epilepsy represent a distinct disease subtype?	195
Evaluation of major national dementia policies and health‐care system preparedness for early medical action and implementation	179
Education, neighborhood environment, and cognitive decline: Findings from two prospective cohort studies of older adults in China	176
Impaired glymphatic function as a biomarker for subjective cognitive decline: An exploratory dual cohort study	170
Trajectories of cognitive decline and dementia development: A 12‐year longitudinal study	163
Cerebral small vessel disease burden and cognitive and functional outcomes after stroke: A multicenter prospective cohort study	162
Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)	157
Cis p‐tau underlies vascular contribution to cognitive impairment and dementia, but is effectively targeted by immunotherapy	151
The Global Neurodegeneration Proteomics Consortium ‐ Biomarker and Drug Target Discovery Across >40,000 Biosamples for AD, PD, ALS, FTD, and Aging	146
The Design of SPRINT MIND and SPRINT MIND 2020	136
Survey on knowledge of Uruguayan neurologist about the FINGER intervention	133
Rapid discovery and optimization of novel brain shuttles and shuttle‐enabled anti‐amyloid therapeutics using multiplexed in vivo biologics design	133
Approach for developing interpretative cut‐points during implementation of a plasma p‐tau217 assay in the clinical laboratory	124
Use of a blood‐based amyloid test for screening in INVOKE‐2: a phase 2 randomized, double‐blind, placebo‐controlled study evaluating AL002 in early Alzheimer’s disease	122
Exploring Alzheimer’s disease progression through the lens of genetics and sleep disturbances	112

The power of cognitive rehabilitation in Alzheimer’s disease ‐A Systematic review and meta analysis	112
Examining the impact of hormone therapy and Alzheimer’s disease risk factors on depressive symptoms in the Harvard Aging Brain Study	109
Relationship between perivascular spaces and white matter hyperintensities in Alzheimer’s disease	106
Social Engagement as a Protective Factor for Cognition in Older Adults: Examining Sex and Race Differences	103
The Types and Consistency of Participant‐Specified Proxies During SPRINT	97
Neural flexibility as a promising biomarker for Alzheimer’s Disease	97
Influence of tau on non‐traditional memory scores in early‐onset Alzheimer’s disease	94
Clinical validation of the Eli Lilly SPX P‐tau217 blood‐based immunoassay as a laboratory‐developed test (LDT)	87
Social frailty and the incidence of motoric cognitive risk syndrome in older adults	84
Mendelian randomization highlights causal association between genetically increased C‐reactive protein levels and reduced Alzheimer's disease risk	84
CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease	79
Longitudinal multicenter head‐to‐head harmonization of tau‐PET tracers: an overview of the HEAD study cohort	79
An international core outcome set for primary progressive aphasia (COS‐PPA): Consensus‐based recommendations for communication interventions across research and clinical settings	78
Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium	78
Rationale for an anti‐inflammatory insulin sensitizer in a phase 3 Alzheimer's disease trial	77
Association of air quality reduction with incident dementia: Effects of natural course and hypothetical air pollutant interventions using g‐computation	76
Intracranial arteriosclerosis and the risk of dementia: A population‐based cohort study	76
The use of the Cognitive Change Questionnaire by community health workers as dementia screening method	74
Fish intake and MRI burden of cerebrovascular disease in older adults	72
The impact of the COVID‐19 pandemic on cognitive health	72
Association of anticholinergic medication and AD biomarkers among cognitively normal late middle‐age adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP)	71
The effect of prolonged lockdown due to COVID‐19 on demented patients of different stages and on their caregivers	71
Association of neighborhood socioeconomic disadvantage and cognitive decline	71
The dementia policies in Australia relating to the COVID‐19 pandemic	70
Assessing sex differences between mid‐life cardiovascular conditions or risk factors and mid‐life cognition decline	70
The association between diabetes and Alzheimer’s disease pathophysiology	69
Policy recommendations from the perspective of health professionals who work with people with dementia in public tertiary hospitals in China	69
Outreach and recruitment of African Americans for Alzheimer’s disease studies during the COVID‐19 pandemic	68
Trajectories of self‐rated concerns in individuals developing cognitive decline	68
Iron intake, brain iron, and Alzheimer’s disease among community‐dwelling older adults	68
The troubles and needs of family caregivers of older adults with moderate to severe dementia	67
Feasibility of the occupational therapy protocol TAP (Tailored Activity Program) for the management of behaviors in a dementia hospital unit: Preliminary results from a pilot study	66
Speed of cognitive decline in biomarker stratified SCD subgroups	66
Using an entorhinal cortex‐based virtual reality navigation task to differentiate between individuals with and without subjective cognitive decline	65
Discerning neurodegenerative and aging genetic influences on hippocampal subfields trajectories in the Alzheimer’s disease continuum	65
Regional correlation analysis between neuronal metabolism and synaptic density using [18F]FDG and [11C]UCB‐J	65
Exploring Inflammasome/Cytokine/Insulin cascade as converging landscape for AD, Schizophrenia(SCHIZO), and COVID‐19 syndrome: synthesis of evidence and Post‐hoc analysis of Ginsans‐115 RCT in treatmen	65
Automating the verbal paired associates test to assess memory remotely and at scale	65
A simple, automated, speech‐based and AI‐enhanced screener for mild cognitive impairment and amyloid beta positivity	62
A systematic evaluation of hippocampal GABA levels in transgenic mouse models of amyloid and tau	61
Short antibiotic treatment followed by regular administration of acid suppressant (proton pump inhibitor) reduce AB42 load in the brain and in the gut.	59
Neuropathology of a patient with AD treated with low doses of verubecestat	59
Transient CSF1R Inhibition in the Early Stage of AD Retains Homeostatic Microglia with Reduced Inflammasomes and Increased autophagy in the 5XFAD Model	59
A Placebo‐Controlled Phase I Study in Healthy Subjects Assessing NVG‐291, which Targets CNS Receptor Protein Tyrosine Phosphatase Sigma (PTPσ)	59
β‐secretase inhibition prevents structural spine plasticity deficits in AppNL‐G‐F mice	58
TREM2 Burden associates solely with Alzheimer’s Disease, and decreases the Chance to become a Centenarian	57
Whole‐exome sequencing of a Portuguese cohort of early‐onset Alzheimer’s disease implicates X‐linked lysosomal gene GLA	56
Human postmortem studies as a driver of biomarker development	56
Association of Epigenetic Aging with Cognitive Aging in Diverse Hispanics/Latinos	56
Exploring the role of brain DNA methylomic signatures on gene expression dynamics of frontotemporal lobar degeneration	55

Widespread transposable element dysregulation in human brains with Alzheimer’s disease	55
Dynamic Light Scattering Spectroscopy as an Early Biomarker of Alzheimer’s Disease	54
In Vivo Head‐To‐Head Comparison of [¹⁸F]GTP1 and [¹⁸F]PI2620 in Alzheimer’s Disease	54
Validated, unified theory of Alzheimer Disease illuminates two essential research questions	54
Neuroinflammation is associated with the rising of early Alzheimer’s disease pathology in amyloid‐negative elderly	54
Development of an artificial intelligence approach that employs genomic and brain imaging features to improve the diagnosis of Alzheimer’s Disease (AD)	53
Cerebral Small Vessel Disease and Gait Speed in Older Adults without Dementia	53
Addressing the gaps of the functional neuroimaging in young APOEe4 carriers: A systematic review and Graph Theoretical analysis of brain connectivity	53
Antagonistic Amyloid‐β and tau interactions with T1‐weighted/T2‐weighted magnetic resonance ratio in Alzheimer’s disesase continuum	52
CASBA neurological assessment: Noninvasive EEG biomarkers classify amyloid‐PET, clinical diagnosis, cognitive dementia rating, and FCSRT free recall scores in patients with cognitive decline	52
From identification to implementation: state of the art in biomarkers for immune function in CSF and blood	52
White matter hyperintensities: A long‐term consequence of repetitive head impacts?	52
Automated word class and person usage metrics as markers of Alzheimer’s and frontotemporal dementia	52
Anti‐ulcer drug teprenone clinical trial	51
PDE5 inhibitors against synaptic and cognitive impairment in Alzheimer’s disease and related dementia	51
Synthetic FDG‐PET hypometabolism sensitivity validation in AD	50
WVE‐005, a stereopure antisense oligonucleotide for MAPT silencing in tauopathies	50
Brain‐Penetrable Antibody Probes for in vivo Tau Imaging	49
CSF Biomarkers and [¹⁸F]flutemetamol PET‐Derived Centiloids in Patients with SCD or MCI	49
Reconsideration of appropriate use criteria for amyloid PET based on real‐world experiences	49
Cerebral perfusion and amyloidosis in the oldest‐old	49
A 5‐hydroxymethylation‐based clock derived from cell‐free DNA in blood reveals accelerated epigenetic aging in patients with Alzheimer’s disease	48
TMS‐based measures of cortical excitability are related to distributed atrophy in early Alzheimer’s disease	48
PAS‐MCI: Design and rationale for a randomized controlled trial to enhance prefrontal cortical plasticity and working memory in individuals with amnestic mild cognitive impairment	48
Astrocyte reactivity is associated with synaptic dysfunction across the aging and Alzheimer’s disease spectrum, whereas microglial reactivity is specifically associated with synaptic dysfunction relat	48
Observations on biomarkers in Roche Abeta‐targeting monoclonal antibody trials	47
A portable eye tracking experiment for the assessment of cognitive impairment in presymptomatic frontotemporal dementia	47
Plasma biomarkers, memory impairment, and imaging measures of Alzheimer’s disease in American Indians	47
Combined effect of prebiotic and probiotic strains restores cognitive impairment via attenuating synaptosis in the hippocampus of mice fed with high fat diet and streptozotocin diabetes‐induced dement	47
Automated lexical analysis of story recall in healthy controls	46
Using an integrated multi‐omics approach to predict dementia: Explainable variational autoencoder (E‐VAE) classifier model	46
Elderly Role Performance Occupational Therapy	46
A retinal tauopathy with a characteristic molecular pattern points to the existence of a “Primary retinal tauopathy”	46
Plasma phosphorylated tau 181 and modifiable risk factors for dementia in a large scale cohort of Australian older adults	46
Explainable AI and its instantiation in Computational Pathology for a better understanding of Alzheimer’s disease	46
The App^NL‐G‐F/MAPT mouse model of Alzheimer’s Disease demonstrates increased levels of ptau217 in CSF, changes that correlate with increased cerebral p‐tau depositions	46
Determination of molecular chaperone levels in cerebrospinal fluids of Alzheimer’s patients	46
Baseline and Six‐Month Actigraphy and Sleep‐monitoring Devices Help Differentiate Between Alzheimer’s Disease and Dementia with Lewy Bodies	46
Impact of the COVID‐19 Pandemic on Patients with Dementia or Parkinson’s Disease and their Caregivers in Lima, Peru	45
Exploring Narrative Identity via Linguistic Positioning in the Context of Alzheimer’s Dementia Risk Prediction – an Ethical and Linguistic Analysis	45
Impact of learning amyloid PET results on test‐related distress and concern about dementia in a cognitively unimpaired observational cohort	45
Perceptions of Shared decision making in cognitive impairment of LTC recipients	45
Tolerability and Likeability of a Cognitive Training Program in an Outpatient Memory Care Clinic	45
Longitudinal patterns of behavioral and psychological symptoms of dementia in community‐dwelling older people	45
Dementia‐inclusive radio series ‘Talkin’ About Neurodegeneration'—A look under the dementia umbrella and a follow‐on series to award‐winning ‘Voyage Around My Brain’ on NearFM	44
Transgender adults report greater cognitive and related functional challenges: Findings from the 2015‐2019 Behavioral Risk Factor Surveillance System	44
Biomarker driven enrichment strategies for tau pathology in AD clinical trials	44
The heterogeneity of subjective cognitive decline: A data‐driven approach on a population‐based sample	43
Functional connectivity measurements in APP/PS‐1 mice revealed hypo‐connectivity with transient hyper‐connectivity	43
Combination of baicalein and trans‐chalcone synergistically reduces amyloid beta and its toxicity in yeast	43
Cognitive correlations with amyloid, tau and neurodegeneration PET across the Alzheimer’s disease age spectrum	43
Improved functional connectivity after a 6‐month ketogenic supplementation in mild cognitive impairment	43
Comparing associations of Alzheimer’s disease plasma biomarkers with remote self‐administered cognitive measures versus in‐person neuropsychological tests	42
A 10‐minute Digitally Administered and Scored Neuropsychological Protocol Assessing Executive Control and Episodic Memory	42
Identification of objective cognitive decline in preclinical Alzheimer’ disease	42
A Study of Factors Influencing Quality of Life among Community Dwelling Elderly in Korean Urban Community	42
Decline in everyday functioning in relation to cerebral tau burden across the clinical spectrum of Alzheimer’s disease	42
Non‐Invasive Temporal Interference Hippocampal Stimulation in Early Alzheimer’s Disease	41
Incorporating clinical trial outcomes in health economic evaluations of disease‐modifying therapies for AD	41
Unsupervised Learning‐based Drug Repositioning for Alzheimer’s Disease Targeting Brain Cell Type Specific Genetic Subtypes	41
Clinical outcome assessments for LBD trials – Should we borrow?	40
Issue Information	40
The association between air pollution and dementia: results from the Cognitive Function and Ageing Study II and Wales	40
Preliminary Evidence for the Combined Efficacy of Focused Ultrasound Blood‐Brain Barrier Opening and Delivery of a Novel Anti‐Amyloid Re Complex for Memory Improvement in a 3xTg‐Alzheimer’s Disease Mo	40
Comparative Pharmacokinetic Studies of One‐Month Donepezil IM Depot and Once Daily Oral Tablet in Healthy Male Volunteers	40
Development of pyroptosis inhibitors for Alzheimer’s disease	40
Microglial‐targeted nSMase2 inhibitor fails to reduce tau spread in the animal model of Alzheimer’s disease	40
Comparative efficacy of cholinesterase inhibitors and memantine on cognition in AD patients with application of network meta‐analysis	40
Study Design of FINGER‐NL: a Multidomain Lifestyle Intervention in Dutch Older Adults to Maintain Optimal Cognitive Functioning	40
CD33 competitive inhibitor peptide IMAD‐001 modulates innate immunity in Alzheimer’s disease	39
Prevalence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population	39
Delivery of incretin receptor agonists to the brain	39
Impact of Mid‐ and Late‐Life Diabetes in the Trajectories of Cognitive Aging in a Bi‐ethnic Cohort of Mexican Americans and Non‐Hispanic White Older Adults	39
Impact of Site Size on Data Quality in Early Alzheimer’s Disease Clinical Trials	39
Cognitive impairment prevention and healthy aging. A multidisciplinary team work	38
Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology	38
Preventing cognitive decline using portable, non‐invasive sleep enhancement.	38
Comparison of Vascular Health in Super‐Agers and Cognitively Normal Adults 80 Years and Older	38
Prevalence of risk factors for dementia and association with cognitive alterations in an elderly population from the South of Brazil	38
Analytical Choices of Timescale in the Presence of Practice and Cohort Effects in Longitudinal Cognitive Aging Research: A Simulation Study Using Linear Mixed‐Effects Models	38

A Rule‐Based Framework to Identify Severity of Dementia from Unstructured Electronic Health Record Data	38
	38
Inflammation and working memory performance in everyday life: Gender differences among older adults with and without cognitive impairment	37
A Comparison of the Prevalence of Diabetes between Aging Rural and Urban Indians.	37
Sex modifies the associations of regional fat with cognitive functioning and AD‐related brain volumes, in Israeli middle‐aged adults at high AD risk	37
Transition in the cognitive continuum from normal cognition to dementia: the interplay of lifelong cognitive reserve with brain aging and genetic predisposition	37
Recruitment data of the HAPPCAP‐AD (Human‐APPlication Combined Approach for Prevention of Alzheimer’s Disease): a feasibility study	37
COVID‐19 Infection and Dementia: Analyses of time‐varying risk, subtypes, and subpopulations from the UK Biobank	37
Reducing Risk of ADRDs: Innovative Framework to Inform Behavior Change	36
Are there trends towards compression of morbidity for dementia? Evidences from four international population‐based cohorts	36
Improvement of Knowledge and Research Attitudes on Preclinical Alzheimer’s Disease Trials through Community‐based Education Among Underrepresented Korean, Filipino, and Hispanic Americans	36
Social media responses to the approval of lecanemab in Japan: sentiment analysis	36
Relation Between Educational Attainment and Cerebral Small Vessel Disease: the Framingham Heart Study	36
Impact of Metabolic Syndrome Longitudinal Changes on Cognitive Health: A 10‐Year Follow‐up Study in Middle‐Aged Adults	36
Characterising the covariance pattern between lifestyle factors and structural brain measures: a multivariable study of two cohorts of older adults	36
Cognitive symptoms and medical history prior to mild cognitive impairment and dementia diagnosis: a retrospective case‐control study using Dutch primary care data	36
Additive Impact of Cardiometabolic Multimorbidity and Depression on Cognitive Decline: Findings from Multi‐Regional Cohorts and Generalization from Community to Clinic	36
Comparison of remote and in‐person digital speech‐based measures of cognition	35
Relationship between amyloid and tau levels and its impact on tau spreading	35
Association of life‐course traumatic brain injury with the risk of dementia: a nationwide twin study	35
Engaging and Recruiting Latino‐led Community Organizations to Build Workforce Capacity in AD/Brain Health Prevention Research	35
Visual memory test equal to commonly used verbal memory test in predicting tau in the medial temporal lobe	35
Issue Information	35
Social Engagement is associated with better cognition in Quilombola Communities: Insights for Engaging underserved Brazilian Populations in Alzheimer’s Disease Research	35
Memory decline is not normal, healthy brain aging	35
The chauffeur who banged cars happily: an interesting case of rapidly progressive strategic infarct dementia	35
Baseline Frailty and Domain‐specific Cognitive Declines in Healthy and MCI Older Adults	35
Analysis of the ACE‐R’s sub‐items that best differentiate healthy controls, amnestic MCI and non‐amnestic MCI	35
Meaning from tragedy: exploring attitudes toward dementia patient participation in research	34
LANGaware: Introducing the right solution for the early detection of neurodegenerative and psychiatric diseases	34
Decorin is an early CSF biomarker of Alzheimer’s Aβ amyloidosis	34
Issue Information	34
Autophagy and lysosomal defects in cells expressing disease‐associated tau	34
Impairment of auditory integration in subjective cognitive decline, amnestic mild cognitive impairment, and Alzheimer’s disease	34
	34
Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer’s continuum	34
Correction to “Using remote, digital, multi‐day testing to characterize long‐term forgetting in cognitively unimpaired older adults”	33
Integrated analysis of in vivo retinal perivascular amyloid imaging and cognition	33
Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study	33
Concordance and diagnostic accuracy between Innotest and two fully automated platforms: Elecsys and Lumipulse	33
A brain DNA co‐methylation network analysis of psychosis in Alzheimer's disease	32
High Social Deprivation as a Risk Factor for Dementia: Findings from the longitudinal SHARE study of older Europeans	32
Longitudinal white matter hyperintensities in Down’s syndrome	32
Applying novel EMBRACE technological solutions to measure and optimize brain response to exercise.	32
Developing machine‐learning‐based amyloidogenicity predictors with Cross‐Beta DB	32
Short‐term Sirolimus Treatment Restores Hippocampus and Caudate Volumes and Global Cerebral Blood Flow in Asymptomatic APOE4 Carriers Compared with Non‐carriers	32
Microvascular Morphology MR Imaging Using Relaxation Rate Change with Gadolinium‐Based Contrast Agent in Patients with Alzheimer’s Disease	32
Innovative Methods to Gather, Understand, And Incorporate Diverse Lived Experiences Into Dementia Research	32
How well is Brazil prepared for a disease‐modifying Alzheimer’s treatment?	32
Bibliographic Analysis of Aging Anxiety and Lifestyle	32
Diffusion MRI subnetwork efficiency is associated with cognitive resilience to AD pathology in cognitively unimpaired older adults at risk of AD dementia	32
The moderating effect of APOE E4 on the association of plasma biomarkers with markers of cognition and brain health in Alzheimer’s disease	32
The potential protective benefit of personality on subjective cognitive decline related worry: Results from the Canadian Longitudinal Study on Aging (CLSA)	32
Tau‐PET imaging with ¹⁸F‐PI‐2620 reveals lateralized distribution of tau pathology in critical language regions in patients with early onset of Alzheimer’s Disease and patients with primary	32
Alzheimer's disease‐induced phagocytic microglia express a specific profile of coding and non‐coding RNAs	32
Differential Effects of Anticholinergic Medications in a Human Neuronal Model of AD	31
Syzigium aromaticum may protect against paraquat mediated toxicity via p53 and Sestrin2 modulation	31
Reduced density of serotonergic axons without prominent neuron loss or tau pathology in the dorsal raphe nucleus in App knock‐in mouse models of amyloid‐β pathology	31
Racial differences in white matter hyperintensity load in aging, MCI, and AD	31
Amyloid‐β Pathology Exacerbates Aging‐Induced Dysregulation of C1q Expression in Cortical Neurons	31
Ameliorative effects of Aqueous Fruit Pulp Extracts of Adansonia digitata on the Hippocampus of Aluminium Chloride‐treated Adult Wistar Rats	31
Racial disparities in Alzheimer’s Disease (AD): Correlating a novel neuropsychological screening test to established AD fluid and imaging biomarkers in African Americans and Caucasians	31
Plasma GFAP:NfL discriminates FTLD‐tau from FTLD‐TDP	31
Impaired retinal capillary function in patients with clinical Alzheimer’s disease	31
Associations between blood‐based biomarkers and other outcomes related to Alzheimer’s disease	30
Depression in Alzheimer’s disease hospitalized patients: A descriptive analysis of a nationwide database	30
APOE loss‐of‐function variants: Compatible with longevity and associated with resistance to Alzheimer’s Disease pathology	30
The effect of virtual reality and physical exercise training on cognitive function in older adults with mild cognitive impairment	30
Relationships between cerebral tau and glucose metabolism in cognitively normal older adults	30
Putative Cellular Identity of Dystrophic Neurites in FTLD‐TDP Type C	30
Association between plasma inflammatory biomarkers and [¹⁸F]FDG‐PET signal in a transgenic amyloid rat model	30
Risk knowledge and risk perception of MCI patients and their caregivers in predictive diagnosis of AD: Findings from the PreDADQoL study	30
Clinical profile of primary progressive Aphasia in Peru: Case series from a Neurological care center	30
Is QEEG an effective biomarker in predicting cognitive decline?	29
CSF tau phosphorylation at sites 217 and 181 are associated with preclinical and biphasic alterations in resting‐state functional connectivity in Autosomal Dominant AD	29
Dissipating the fog: Cognitive trajectories and risk factors 1 year after COVID‐19 hospitalization	29
APOEε4 facilitates the accumulation and connectivity‐mediated spreading of tau pathology at lower amyloid levels	29
Usability experience of remote sleep monitoring in patients with neurodegenerative diseases	29
The Advanced Therapeutics for Alzheimer’s Disease Review Board: A Multidisciplinary Model to Facilitate Safe Access to Lecenemab across the Sutter Health System	29
Hub vulnerability and short path length to entorhinal cortex are associated with tau binding in Alzheimer’s disease: a combined MEG/PET study	29
	29
Hyperintensity on Diffusion‐Weighted MRI and Clinical Correlations in Probable Creutzfeldt‐Jakob Disease	29
Primary retinal tauopathy: A tauopathy with a distinct molecular pattern	29
Prevalence and pathological correlates of unawareness of memory impairment in non‐demented individuals with autosomal dominant Alzheimer’s disease: an item‐level investigation of the Memory Complaints	29
Premature aging in co‐occurring Alcohol Use Disorder and Post‐Traumatic Stress Disorder from a functional connectome perspective	29
Recognizing human functional patterns in IADLs through hand detection and artificial intelligence	29
Amyloid‐Beta PET Synthesis from Structural MRI: A Potential Alternative Method for Alzheimer’s Disease Screening	29
Increased regional brain inflammation predicts longitudinal brain atrophy in individuals in the Alzheimer’s disease continuum	29
A Machine Learning Approach to Identify Individualized Baseline MRI, Plasma, Cardiovascular and Lifestyle Predictors of a 5‐Year Cognitive Decline	28
Description of the Gut Microbiome Composition in Puerto Ricans with Alzheimer’s Disease Compared to Healthy Controls	28
Movement with Dementia: A feasibility study of a resource to support the personalisation of therapeutic exercise programmes for people living with dementia	28
Understanding differences in antidepressant use patterns among african american and white volunteers with dementia	28
Lithium carbonate treatment decrease neuroinflammation and ameliorates long‐term memory in a Down syndrome animal model	28
Motor alterations associated with cognitive impairment in a third‐level hospital	28
Seizures exacerbate tau spread in the 5XFAD mouse model	28